Regardless which nucleic acids you develop as therapeutics, biomarkers or similar, we offer you the quantification of your nucleic acids and oligonucleotides in various biological matrices. We develop standardized and reproducible methods according to the latest GLP guidelines for many substance groups.
- DNA and RNA
- small non-coding RNAs:
- miRNAs (precursors and mature)
- RNA Therapeutics: AntagomiRs
We support you in many areas of your research. Benefit from our experience in many areas of active substance and biomarker development.
- Active substance or biomarker search/development
- Preclinical studies:
- Dose-finding studies
- Toxicological studies
- Pharmacokinetic studies
- Toxicokinetic studies
- Clinical trials (Phases 0-III)
- bioequivalence studies
For several years we have been conducting intensive research in the field of miRNA analytics. In our project funded by ZIM we have succeeded in establishing a GLP validated analytics for the determination of miRNAs in plasma. In another project we are developing a diagnostic test based on miR-574-5p as a predictive biomarker for the identification of patients with PGE2-mediated tumor growth (here bronchial carcinoma and colorectal carcinoma) who benefit from the application of NSARs and/or mPGES-1 inhibitors.